To estimate relative treatment effects between ravulizumab and approved treatments (eculizumab, inebilizumab, and satralizumab) in adult patients with AQP4-IgG+ NMOSD.
No takes yet. Share an insight, caveat, or question.
Clardy et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: